26 results
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
, we are entitled to offset a specified percentage of amounts paid to such third parties in consideration for such intellectual property rights against … . The availability to carry forward and offset these tax loss carry-forwards against future operating profits is subject to certain restrictions.
As a company
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
proceeds received after offset for the deductions described above) made prior to receipt of all Regulatory Approvals for the Product in any country … with the tax paid, the “Withholding Amount”), the Withholding Party will have the right (a) to offset the Withholding Amount, against future payment
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
to $17.4 million in 2023. The decrease was primarily due to a $12.4 million reduction in R&D expenses for etigilimab, partially offset by an increase
6-K
EX-99.2
MREO
Mereo Biopharma Group Plc
7 Sep 23
Current report (foreign)
7:37am
restrictions, we expect these to be available to carry forward and offset against future operating profits. As a company that carries out extensive research … OncXerna following the global licensing arrangement for navicixizumab and associated payments to CVR holders in 2022, which more than offset
6-K
EX-99.2
MREO
Mereo Biopharma Group Plc
2 Nov 22
Current report (foreign)
4:17pm
these to be available to carry forward and offset against future operating profits. As a company that carries out extensive research and development activities, we … . In 2021, the operating cash expenditure of the Company was offset by the upfront proceeds from Ultragenyx of £36.5 million less the associated payments
6-K
EX-99.2
6u923e plia07
2 Nov 21
Current report (foreign)
4:16pm
F-3/A
jycmd
27 Sep 21
Shelf registration (foreign) (amended)
4:18pm
F-3/A
9fpv xbos
7 Sep 21
Shelf registration (foreign) (amended)
4:06pm
F-3
q0apwz2
5 Aug 21
Shelf registration (foreign)
4:33pm
6-K
EX-99.1
rotp5
16 Apr 21
Current report (foreign)
4:10pm
6-K
EX-99.1
zx6lhqlag3r
31 Mar 21
Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights
5:13pm
F-3
v17k82j4fp2syk
6 Jul 20
Shelf registration (foreign)
4:58pm
6-K
hm4z 9nloz9
16 Jun 20
Current report (foreign)
4:13pm
F-1/A
6qw 9m23m
12 Mar 20
Registration statement (foreign) (amended)
5:15pm
F-1/A
hjbv lv753qg18
6 Mar 20
Registration statement (foreign) (amended)
5:32pm
6-K
xvjjoeesthm298q
17 Sep 19
Current report (foreign)
8:06am